Marina Kremyanskaya, MD, PhD, discusses responses with CPI-0610 in patients with myelofibrosis.
Marina Kremyanskaya, MD, PhD, assistant professor of medicine, hematology and medical oncology at Mount Sinai Hospital, discusses responses with CPI-0610 in patients with myelofibrosis.
Data from the phase II MANIFEST trial suggest that CPI-0610 with or without ruxolitinib (Jakafi) may have disease modifying effects in patients with myelofibrosis who have progressed on or had an inadequate response to ruxolitinib.
CPI-0610 alone and in combination with ruxolitinib led to improved hemoglobin levels in anemic patients, improved bone marrow fibrosis, spleen volume reduction, and symptom improvement in the majority of patients. Additionally, 2 patients who were transfusion-dependent at baseline achieved transfusion-independence with the combination of CPI-0610 and ruxolitinib, says Kremyanskaya.
Both the monotherapy and combination regimens appear to be well-tolerated in this patient population.